Skip to content
2000
Volume 22, Issue 43
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Background: The identification of combinatorial antibodies against many different targets in oncology, autoimmune, inflammatory and infectious diseases has uncovered novel strategies to control and prevent diseases’ onset and progression, and represents the fastest growing market for the pharmaceutical industry. Phage Display has been successfully used in the identification of unknown targets, which combines shotgun approaches with high throughput selection schemes. Methods: This specific review covers many aspects of combinatorial phage display technology starting from antibody selection strategies to its redesign for application purposes. Emphasis is specifically directed to how these biotherapeutics function on specific targets with an interactome view, especially within complex diseases. Conclusion: Novel combinatorial antibodies will lead to improved interventions in cancer, autoimmune and infectious diseases; however, the very large genetic diversity associated with environmental variations highlight the importance of the personalized medicine using a system’s biology approach. Therefore, combined therapies are expected in the near future.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612822666160923112816
2016-12-01
2025-04-20
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612822666160923112816
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test